阿帕替尼联合SOX方案治疗Ⅲb~Ⅳ期胃癌患者的临床疗效  

Clinical efficacy of apatinib combined with SOX regimen in the treatment of patients with stage IIIB-IV gastric cancer

作　　者：夏国盛 刘路 钟佳 XIA Guosheng;LIU Lu;ZHONG Jia(Department of Gastroenterology,Ji’an Central People’s Hospital,Ji’an 343000,Jiangxi,China)

机构地区：[1]吉安市中心人民医院消化内科,江西吉安3430000

出　　处：《癌症进展》2024年第24期2769-2772,共4页Oncology Progress

摘　　要：目的探讨阿帕替尼联合替吉奥+奥沙利铂(SOX)方案治疗Ⅲb~Ⅳ期胃癌患者的临床疗效。方法根据治疗方法的不同将60例Ⅲb~Ⅳ期胃癌患者分为对照组(n=31,SOX方案治疗)和观察组(n=29,阿帕替尼联合SOX方案治疗)。比较两组患者的临床疗效、血管内皮生长因子(VEGF)水平、肿瘤标志物[癌胚抗原(CEA)和糖类抗原19-9(CA19-9)]水平、无进展生存期(PFS)、总生存期(OS)及不良反应发生情况。结果观察组患者的疾病控制率(DCR)明显高于对照组,差异有统计学意义(P﹤0.01)。治疗后,两组患者VEGF、CEA和CA19-9水平均低于本组治疗前,观察组患者VEGF、CEA和CA19-9水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者的平均PFS和OS均明显长于对照组,差异均有统计学意义(P﹤0.01)。两组患者胃肠道反应、骨髓抑制、乏力及肝功能异常发生率比较,差异均无统计学意义(P﹥0.05)。结论阿帕替尼联合SOX方案治疗Ⅲb~Ⅳ期胃癌患者的疗效显著,可降低VEGF及肿瘤标志物水平,控制疾病进展,延长生存期,且安全性较好。Objective To explore the clinical efficacy of apatinib combined with S-1+oxaliplatin(SOX)regimen in the treatment of patients with stage IIIB-IV gastric cancer.Method According to different treatment methods,60 pa-tients with stage IIIB-IV gastric cancer were divided into control group(n=31,SOX regimen treatment)and observation group(n=29,apatinib combined with SOX regimen treatment).The clinical efficacy,vascular endothelial growth factor(VEGF)level,tumor markers[carcinoembryonic antigen(CEA)and carbohydrate antigen 19-9(CA19-9)]levels,progres-sion-free survival(PFS),overall survival(OS)and adverse reactions were compared between the two groups.Result The disease control rate(DCR)of the observation group was significantly higher than that of the control group,and the difference was statistically significant(P<0.01).After treatment,the levels of VEGF,CEA and CA19-9 in both groups were lower than those before treatment,and the levels of VEGF,CEA and CA19-9 in observation group were lower than those in control group,the differences were statistically significant(P<0.05).The average PFS and OS in the observation group were significantly longer than those in the control group,and the differences were statistically significant(P<0.01).There were no significant differences in the incidences of gastrointestinal reaction,myelosuppression,fatigue and abnor-mal liver function between the two groups(P>0.05).Conclusion Apatinib combined with SOX regimen has significant efficacy in the treatment of patients with stage IIIB-IV gastric cancer can reduce the levels of VEGF and tumor markers,control disease progression,prolong survival,and has good safety.

关 键 词：胃癌 阿帕替尼 SOX方案 血管内皮生长因子 无进展生存期 总生存期 

分 类 号：R735.2[医药卫生—肿瘤]